What is the mechanism of action for Ticlopidine?

Ticlopidine works by irreversibly inhibiting the P2Y12 receptor on platelets. This receptor plays a crucial role in platelet activation and aggregation, particularly in response to ADP (adenosine diphosphate). By blocking the P2Y12 receptor, Ticlopidine effectively prevents the activation of platelets, thereby reducing their ability to form clots. This mechanism is vital in the context of preventing thrombotic events, such as stroke or myocardial infarction, particularly in patients at high risk for these conditions.

The ability of Ticlopidine to provide a long-lasting effect on platelet function is key to its therapeutic use, as platelets that are already activated cannot be reversed to an inactive state once they are inhibited by the drug. This irreversible action distinguishes Ticlopidine from other antiplatelet agents that might work via different mechanisms or have reversible effects.